Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

UMass Amherst professor receives $2 million NIH MIRA grant for trailblazing research

by Medical Finance
in News
UMass Amherst professor receives $2 million NIH MIRA grant for trailblazing research
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

Jianhan Chen, a University of Massachusetts Amherst chemistry and biochemistry and molecular biology professor, has received a five-year, $2 million National Institutes of Health (NIH) grant to support research in his computational biophysics lab aimed at better understanding the role of intrinsically disordered proteins (IDPs) in biology and human disease.

The grant falls under the National Institute of General Medical Sciences MIRA program, which stands for Maximizing Investigators’ Research Award. It’s designed to give highly talented researchers more flexibility and stability to achieve important scientific advances in their labs.

The MIRA award enables us to continue working on several central problems regarding the study of disordered proteins and dynamic interactions. The flexibility of this funding mechanism also allows us to follow new research directions as they emerge.”


Jianhan Chen, University of Massachusetts Amherst chemistry and biochemistry and molecular biology professor

Until relatively recently, it was thought that proteins needed to adopt a well-defined structure to perform their biological function. But about two decades ago, Chen explains, IDPs were recognized as a new class of proteins that rely on a lack of stable structures to function. They make up about one-third of proteins that human bodies make, Chen explains, and two-thirds of cancer-associated proteins contain large, disordered segments or domains.

“This disorder seems to provide some unique functional advantage, and that’s why we have so much disorder in certain kinds of proteins,” Chen says. “These IDPs play really important roles in biology, and when something breaks down, they lead to very serious diseases, like cancers and neurodegenerative diseases.”

In his lab, Chen and colleagues focus on using computer simulations to model the molecular structure and dynamics of proteins. “IDPs are a mess; it’s difficult to determine the details of their properties because they are not amenable to traditional techniques that are designed to resolve stable protein structures,” he says.

Because of their chaotic state, IDPs must be described using ensembles of structures, and computer simulations play a crucial role in the quantitative description of these disordered ensembles. “Our goal is really trying to combine simulation and experiments in collaboration with other labs to tease out what are the hidden features of these disordered proteins that are crucial to their function,” Chen says. “Then we can look at how these specific features might be perturbed by disease-related mutations or conditions.”

The next step would be to develop effective strategies for targeting disordered protein states. Toward that end, Chen’s lab will study the molecular basis of how the anti-cancer drug EGCG, an antioxidant found in green tea extract, and their derivatives interact with the p53 gene, a tumor suppressor and the most important protein involved in cancer.

The key, he says, is knowing how to design drug molecules to bind well enough to IDPs to achieve a therapeutic effect. Traditional, structure-based drug design strategies are faced with significant challenges, Chen says, because IDPs do not contain stable, “druggable” pockets.

“We believe that targeting IDPs requires new strategies that explore the dynamic nature of IDP interactions,” Chen says. “If we can do this, it could really open up a whole class of drugs that were previously thought impossible.”

Source:

University of Massachusetts Amherst

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

New approach using RNA therapeutic can fix protein problems in cystic fibrosis

Pathogen works with drug to clear fungal infection, study shows

by Medical Finance
May 28, 2022
0

Pathogens don't always work against drug treatments. Sometimes, they can strengthen them, according to a new University of Maine study....

First patient-derived stem cell model developed for studying oculocutaneous albinism

Cell’s production of lipids can be a key factor in determining cell fate

by Medical Finance
May 28, 2022
0

How does a cell "decide" what type of cell to become? The question of "cell fate" has been explored for...

Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

Lab grown, self-renewing muscle stem cells can repair muscle tissue damage in mice

by Medical Finance
May 28, 2022
0

In proof-of-concept experiments, Johns Hopkins Medicine scientists say they have successfully cultivated human muscle stem cells capable of renewing themselves...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

ST6Gal-I–mediated sialylation of the EGFR modulates cell mechanics and enhances cancer invasion

by Medical Finance
May 29, 2022
0

For more than two decades, University of Alabama at Birmingham researcher Susan Bellis, Ph.D., has studied how the addition of...

DeNovix receives customer service company of the year award

DeNovix receives customer service company of the year award

by Medical Finance
May 28, 2022
0

DeNovix Inc, a developer and manufacturer of instrumentation and assays for the life sciences, has been awarded the prestigious Customer...

Study: Evaluation of binding performance of bioactive compounds against main protease and mutant model spike receptor-binding domain of SARS-CoV-2: Docking, ADMET properties and molecular dynamics simulation study. Image Credit: Juan Gaertner / Shutterstock.com

Acacetin shows potency against SARS-CoV-2 spike protein

by Medical Finance
May 28, 2022
0

In a recent Journal of the Indian Chemical Society study, researchers use molecular docking to screen 12 phytocompounds and evaluate...

Next Post
Natural extracellular vesicles containing ACE2 protein could fight new SARS-CoV-2 variants

A promising approach for COVID-19 prophylaxis

Study: Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children. Image Credit: anon_tae/Shutterstock

Study evaluates heterologous vaccination scheme in children using two SARS-CoV-2 RBD protein vaccines

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Maternal-Fetal Implications of SARS CoV-2 Infection during Pregnancy, Viral, Serological Analyses of Placenta and Cord Blood. Image Credit: Rinanda Adelia/Shutterstock
    Pregnancy outcomes of pregnant women infected by SARS-CoV-2
  • Anatomical structure of biological animal cell with organelles eranicle 1d73b50575dc4546875a4a2fc7d429a6 620x480
    Surprising discovery opens new avenues for in vitro organ culture
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply